AGEN.NASDAQAgenus INC

Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Cash Salary

Sentiment:

SEC Form 4 Filing


Agenus Inc. CEO Garo H. Armen received 7,886 shares of common stock as compensation in lieu of cash salary for the pay period ending April 18, 2025.

Summary

  • Garo H. Armen, CEO of Agenus Inc., received 7,886 shares of Agenus common stock on April 18, 2025, as part of his compensation in lieu of cash.
  • The stock was issued at a price of $2.08 per share, which was the closing price of Agenus common stock on April 17, 2025.
  • These shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested upon issuance.
  • Dr. Armen also indirectly owns 175,800 shares through IRA accounts and 28,950 shares as trustee and general partner.
  • He disclaims beneficial ownership to the extent of his pecuniary interest in Pixie Partners.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a transaction related to executive compensation. The acceptance of stock in lieu of cash could be seen as a positive sign of confidence in the company's future, but it's a fairly standard practice.

Positives

  • The acceptance of stock in lieu of cash salary by the CEO could be viewed positively as it aligns his interests with those of the shareholders.

Industry Context

Stock-based compensation is a common practice in the biotech industry, particularly for companies that may be conserving cash. It aligns management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

  • Stock compensation for executives is a common practice in the biotechnology industry, especially for companies in the development stage like Agenus.
  • Companies such as Moderna and BioNTech also utilize stock options and grants as part of their executive compensation packages.
  • The amount of stock compensation varies widely based on company size, performance, and executive role.

Stakeholder Impact

  • The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.
  • Employees may view the CEO's acceptance of stock in lieu of cash as a positive sign of confidence in the company's future.

Key Dates

DateDescription
04/17/2025Closing price of Agenus common stock was $2.08.
04/18/2025Date of transaction: Garo H. Armen received 7,886 shares of Agenus common stock as compensation.
04/22/2025Date of filing of the Form 4.

Keywords

Agenus Inc., Garo Armen, stock compensation, Form 4, beneficial ownership, equity incentive plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.